Qiagen N.v. · NYSE:QGEN
Qiagen — Morgan Stanley Healthcare Conference (September 2026)
58 slides from Qiagen's conference presentation, September 2026
Slide 1: Committed to solid profitable growth
Committed to solid profitable growth Investor Introduction September 2026 Presentation Titel
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: The value of biology has never been stronger
The value of biology has never been stronger Crucial to Improving Direct impact advancing healthcare on your science for all lives Investor Introduction Presentation Titel 3
Slide 4: QIAGEN solutions are used worldwide by researchers
QIAGEN solutions are used worldwide by researchers - from young scientists to Nobel laureates - and clinical labs Investor Introduction Presentation Titel 4
Slide 5: QIAGEN at a glance
QIAGEN at a glance Highly recurring revenues ~5,700 ~90% Consumables and related employees known as QIAGENers revenues ~10% Instruments >500,000 customers worldwide A global company with scale ~52% Balanced customer markets Americas $2.09 billion sales(1) Sales1 ~34% EMEA R&D continuum ~14% Life Mol
Slide 6: QIAGEN more focused and stronger than ever
QIAGEN more focused and Growth and value stronger than ever ~4-6% CAGR ~$13-14 bn ~$11 bn addressable Life Molecular addressable market QIAGEN (2028) Sciences Diagnostics market customers (2024) ~50% ~50% QIAGEN product Sample technologies Balanced global presence 2025 net sales (%) groups 52 34 14
Slide 7: Leading from the first step in lab workflows
Leading from the first step in lab workflows Samples Sample preparation Detection Insights PCR QIAcuity dPCR #2 Any Genomics / NGS Sample #1 biological technologies QIAGEN Digital Insights #1 sample Diagnostic solutions QuantiFERON #1 QIAstat-Dx #2 Life Sciences Customers Molecular Diagnostics Custo
Slide 8: Strategy: Committed to solid profitable growth
Strategy: Committed to solid profitable growth Our 2028 targets Ongoing focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 ~7% Net sales CER CAGR (2024-28) Drive efficiency and digitization to At least 250 bps fuel growth investments and profitabil
Slide 9: Focusing on attractive opportunities in molecular testing
Focusing on attractive opportunities in molecular testing Product PCR / Nucleic acid Sample technologies Diagnostic solutions NGS / Genomics groups amplification 2025 sales $661 mn $803 mn $309 mn $242 mn Accelerate investments for growth Build on proven leadership QIAcuity #2 QIAstat-Dx #2 QIAGEN #
Slide 10: QIAcuity dPCR
QIAcuity dPCR Quantitative PCR Next-generation (qPCR) QIAcuity dPCR sequencing (NGS) Making high-precision PCR e.g., Gene expression more accessible e.g., Liquid biopsy Lower accuracy High sensitivity and precision In-depth insights and precision More accurate than qPCR and high precision dPCR – Cap
Slide 11: Instruments tailored to varying customer segments
Instruments tailored to varying customer segments Key achievements Scalable systems Low- to high- throughput capabilities QIAcuity One QIAcuity Four QIAcuity Eight QIAcuityDx >3,200 cumulative placements Academia since 2020 launch Overcoming entry barrier vs. qPCR Ease of use Fully integrated Transl
Slide 12: Gene expression: Growing opportunity for QIAcuity
Gene expression: Growing opportunity for QIAcuity A large and growing market What is gene expression? Measuring which genes are turned on or off and by how ~$2.7 bn qPCR addressable market in 2025 Overcome qPCR limitations Improve over qPCR accuracy and much – Essential to Gene expression accounts f
Slide 13: Significant investments into QIAcuity dPCR
Significant investments into QIAcuity dPCR ≥$250 mn QIAcuity net sales CER target (2028) Target Extend Accelerate commercialization new applications into clinical use >3x increase Launch new assays QIAcuityDx of sales specialists for market for gene expression and Cell and Gene enabling MRD and moni
Slide 14: QIAstat-Dx
QIAstat-Dx Use case: 3-year-old with severe but unspecific GI symptoms Traditional testing Syndromic testing Slow diagnosis and treatment Fast diagnosis enabling better decisions can lead to complexities treatment decisions Identifying unknown diseases at speed Day 1 Day 1 One test within and ease o
Slide 15: QIAstat-Dx offers differentiated features
QIAstat-Dx offers differentiated features Key achievements Strong product capabilities Key differentiators Specification QIAstat-Dx Competition Workflow Additional >5,200 cumulative placements efficiency pathogens since launch Hands-on time ~1 min >5 min and safety on panels for for broader qPCR rob
Slide 16: Expanding global presence and differentiated menu
Expanding global presence and differentiated menu ≥$200 mn QIAstat-Dx net sales CER target (2028) Grow installed Small hospitals Medium hospitals Large hospital networks customer Public health labs Regional reference labs National reference labs base Low-throughput High-throughput customers customer
Slide 17: QIAGEN Digital Insights
QIAGEN Digital QIAGEN unlocking the power of genomics Insights Development Genomic data In 2003, the first Today, any human human genome took genome can be read in 13 years 5 hours Sequencing Powerful analytics costs $100 / to understand >$1 bn / genome sequencing run 2000 2010 2020 2030 genomics Th
Slide 18: Top bioinformatics for research to clinical customers
Top bioinformatics for research to clinical customers Key achievements Addressing large customer base Delivering QDI software solutions for NGS workflow #1 Research – in bioinformatics software for research and clinical Scientific discovery Pharma / Biotech 6 Academia Sample prep Library prep NGS an
Slide 19: Case study: Research Advancing drug development
Case study: Research Advancing drug development Pharma challenge QDI pivotal to drug discovery Over 50,000 scientific publications cite our software Key to understanding disease pathways, targets and measure changes 25 of the Top 25 Pharma companies use QDI Significant number of failures without the
Slide 20: Case study: Clinical Enhancing patient outcomes
Case study: Clinical Enhancing patient outcomes Patient situation QDI-enhanced patient outcome Mutation identification and recommendation by QDI Profile Male (early 70s) Targeted therapy leading to life-saving disease remission Diagnosis QIAGEN Clinical Leukemia linked to rare gene mutation Insights
Slide 21: Genoox: The AI-powered software platform
Genoox: The AI-powered software platform Speed Accuracy Confidence Optimized for clinical turnaround AI workflows augmented by scientists Proven across >5.5 million reports Continuous feedback through users AI outputs validated by expert review Gold-standard knowledge databases How we win How we win
Slide 22: Focus on SaaS subscription model and AI to expand market leadership
Focus on "SaaS" subscription model and AI to expand market leadership 2028 goals Coming in 2026 Deepen global commercial reach and +40% 4 new AI-enhanced SaaS transition for sustainable growth SaaS sales specialists commercial offerings Agentic AI interface for >14 NGS data analysis Invest in new AI
Slide 23: Investing to extend market leadership
Investing to extend market leadership ≥$200 mn QDI net sales CER target (2028) Extend leadership in curated Deepen global Invest in new AI and other knowledge commercial reach technologies Expand QIAGEN knowledge base into Adopt SaaS go-to-market Continue advancing software spatial, proteomics and m
Slide 24: Sample technologies: #1 in the first step of every molecular workflow
Sample technologies: #1 in the first step of every molecular workflow Laboratory workflow Differentiated solutions for modular, Valuable Biological Sample PCR integrated workflows molecular sample technologies Fast time to result, scalability insights Critical first step and ease of use dPCR in mole
Slide 25: QIAGEN leading the way in sample preparation
QIAGEN leading the way in sample preparation Comprehensive consumables ANY >350 ANY Key achievements biological sample different sample kits DNA / RNA portfolio e.g., tissue, cells, blood, for manual and target analytes >120 mn including variations QIAGEN preparations serum, wastewater automated pro
Slide 26: Scaling automation for the future
Scaling automation for the future Key initiatives Manual QIAcube Connect EZ2 Connect QIAcube HT QIAsymphony Low-throughput Mid-throughput High-throughput Expand state- of-the-art portfolio NEW QIAmini QIAsymphony QIAsprint Update Connect Connect automation Launch 2026 Launched in 2025 Launched in 20
Slide 27: On the offense expanding our top automation portfolio
On the offense expanding our top automation portfolio ≥$750 mn On Sample technologies track net sales CER target QIAsprint Connect QIAsymphony Connect QIAmini (2028) Launch 2026 Launch February 2026 Commercial launch July 2026 Launch Fall 2026 • High-throughput automation • Fully automated digital •
Slide 28: Extending our Sample tech leadership with single-cell solutions
Extending our Sample tech leadership with single-cell solutions Driving the next wave of growth ~$2.1 bn Expanding Expected single-cell market by 2029 Key applications in oncology, immunology and neurology ~10% CAGR AI-driven 2024 - 2029 Generates data fueling AI-powered drug discovery 3,000+ Adopte
Slide 29: Parse: Breaking single-cell limits
Parse: Breaking single-cell limits Scalable High quality AI ready Designed for next-gen biology Validated for consistent performance Built for translational reality >1,000x higher single-cell scale Data quality determines value at AI models need biologically diverse reported over the last 10 years s
Slide 30: QuantiFERON: Tuberculosis market
QuantiFERON Tuberculosis: A highly contagious and lethal bacterial infection 1 in 4 Broad health risk Global relevance people have a latent TB bacterial infection 1 in 10 EMEA of these people will develop an Immunocompromised ~10 mn active TB bacterial infection patients North America Japan >75 mn A
Slide 31: Best-positioned test for latent TB detection
Best-positioned test for latent TB detection QuantiFERON Tuberculin Key achievements Advantages over Specification blood test skin test skin test $503 mn Customizable automated workflow High accuracy and specificity 2025 net sales (+110% vs. 2019) Only one patient visit Electronic results >160 mn Qu
Slide 32: Driving skin test conversion with unrivaled automation
Driving skin test conversion with unrivaled automation ≥$600 mn QuantiFERON Leading automation advantage net sales CER target (2028) Increase Automated Automated liquid handling assay and result Partnership with customer base Diasorin to expand into Lyme disease (EU and U.S.) Large potential in skin
Slide 33: Creating a complete QuantiFERON ecosystem
Creating a complete QuantiFERON ecosystem 37°C Blood collection Aliquotation Incubation Centrifugation Detection Data analysis Current QuantiFERON workflow Manual intervention steps Announcing a new QuantiFERON ecosystem NEW AI-enabled Fully automated Sample to Insight workflow New chemistry risk st
Slide 34: Expanded ecosystem enables full automation and improves efficiency
Expanded ecosystem enables full automation and improves efficiency Addressing the need to improve pre-analytical steps in labs QIAGEN fully automates the process with Inpeco and Diasorin partnerships Process automation can be adapted to specific customer needs Ambition to be the first FDA-approved,
Slide 35: Initiatives to fuel growth investments and achieve ≥31% adjusted operating margin
Initiatives to fuel growth investments and achieve ≥31% adjusted operating income margin in 2028 Operational excellence Digitization Positioning QIAGEN for stronger profitable growth Accelerating growth and efficiency across QIAGEN Organizational design Portfolio streamlining >3.5 million ~30 commer
Slide 36: Executing our strategy with empowered QIAGENers
Executing our strategy with empowered QIAGENers ~5,700 QIAGENers Expand our culture of empowerment ~50% new top leaders since 2020 Foster accountability and decentralized decision-making ~15% with QIAGEN for >15 years Investor Introduction 36
Slide 37: Embracing ESG for all stakeholders
Embracing ESG for all stakeholders Net zero Top ESG ratings Environmental responsibility carbon emission target (2050) Investing in people 37% female leadership (2025) Serving society 75.7 Service NPS-T score exceeding goal of 64.5 (2025) Business with integrity 94% completion rate for Code of Condu
Slide 38: Q2 2026 results
Q2 2026 results Committed to solid profitable growth August 5, 2026
Slide 39: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 40: Q2 2026: Solid performance exceeding outlook
Q2 2026: Solid performance exceeding outlook Growth Q2 2026 net sales ahead of outlook with growth pillars driving performance $535 mn ($531 mn CER) • 0% CER, ahead of the outlook for ~-2% CER decline Net sales • Sales from growth pillars increased 5% CER, led by Sample tech, QIAcuity and QDI 0% CER
Slide 41: Q2 2026: Sales performance and key developments
Q2 2026: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) 0% Sample • +9% CER growth, +3% CER growth excl. Parse CER(1) technologies • Automated consumables delivered high teens CER growth 534 535 • +1% CER growth with solid trends outsid
Slide 42: Q2 2026: Portfolio developments
Q2 2026: Portfolio developments Sample technologies: QIAGEN Digital Insights: QIAstat-Dx: Expanding automated sample preparation Accelerating biomedical research Advancing syndromic testing solutions Progressing rollout of new automation NVIDIA collaboration to advance AI Launch of QIAstat-Dx panels
Slide 43: Q3 and FY 2026: Outlook and assumptions
Q3 and FY 2026: Outlook and assumptions (As of August 5, 2026) Q3 2026 outlook FY 2026 outlook Net sales ~+1-2% CER ~+1-2% CER Anticipated currency impact(1) Negative impact of ~-1 ppt Positive impact of ~+1 ppt Adjusted diluted EPS(2) ≥$0.62 CER ≥$2.43 CER Anticipated currency impact(1) Neutral Neu
Slide 44: Appendix
QIAGEN Appendix
Slide 45: 2026 sales outlook: H1 vs. H2 updated perspectives
2026 sales outlook: H1 vs. H2 updated perspectives ~+0.5 ppt ~+3-4% CER ~+2 ppts Above outlook of ~ -1-2% CER ~+2 ppts -1% CER H1 2026 growth End of NeuMoDx, New Sample tech Better U.S. Life H2 2026 growth including better Dialunox headwind systems, new Science environment outlook QuantiFERON growth
Slide 46: Disciplined capital allocation to drive long-term value
Disciplined capital allocation to drive long-term value Profitable targeted investments Annual dividend Organic into growth pillars and digitization to fuel profitable Dividend approval at the AGM in investments June 2026 business expansion $0.35 dividend per share (~$72 mn payment in July 2026) Foc
Slide 47: Q2 2026: Consolidated Statements of Income
Q2 2026: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended June 30, 2026 June 30, 2025 Net sales 535,040 533,540 Cost of sales: Cost of sales 181,973 185,951 Acquisition-related intangible amortization 12,681 13,303 Total cost of
Slide 48: H1 2026: Consolidated Statements of Income
H1 2026: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Six months ended Six months ended June 30, 2026 June 30, 2025 Net sales 1,027,360 1,016,996 Cost of sales: Cost of sales 351,432 347,245 Acquisition-related intangible amortization 25,939 26,784 Total cost of
Slide 49: 2026: Quarterly sales by product group
2026: Quarterly sales by product group Q1 2026 Q2 2026 Q3 2026 Q4 2026 FY 2026 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 170 13% 9% 182 9% 9% 352 11% 9% Diagnostic solutions(1) 185 -1%
Slide 50: 2026: Quarterly sales by product type and region
2026: Quarterly sales by product type and region Q1 2026 Q2 2026 Q3 2026 Q4 2026 FY 2026 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 445 2% -1% 484 2% 1% 928 2% 0% revenu
Slide 51: Q2 and H1 2026: Reconciliation to adjusted results
Q2 and H1 2026: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* Second quarter 2026 Reported results 535.0 340.4 132.4 132.1 (28.7) 22 % 103.4 0.50 Adjustments Business integ
Slide 52: Footnotes for reconciliation to adjusted results
Q2 and H1 2026: Footnotes for reconciliation to adjusted results (unaudited) (a) Includes costs incurred in connection with streamlining operations and improving overall efficiency as well as costs related to various contemplated and completed acquisition projects including subsequent integration ac
Slide 53: 2026: Quarterly income statement summary
2026: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2026 Q2 2026 Q3 2026 Q4 2026 FY 2026 Net sales 492.3 535.0 1,027.4 Net sales (CER) 476.7 531.1 1,007.9 Gross profit 309.6 340.4 650.0 Gross profit margin 62.9% 63.6% 63.3% Adjusted gross profit
Slide 54: Consolidated Balance Sheets
Consolidated Balance Sheets December 31, June 30, 2026 December 31, (In $ thousands, except par value) June 30, 2026 2025 (In $ thousands, except par value) 2025 Assets (unaudited) Liabilities and equity (unaudited) Cash and cash equivalents 768,500 839,005 Current portion of long-term debt 16,517 —
Slide 55: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (unaudited) Six months ended Six months ended (In $ thousands) June 30, 2026 June 30, 2025 (In $ thousands) June 30, 2026 June 30, 2025 Cash flows from operating activities: Cash flows from financing activities: Net income 171,444 187,008 Capital repayment (496,
Slide 56: Q2 and H1 2026: Currency impact
Q2 and H1 2026: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q2 2026 U.S. dollar 309.4 309.4 58% 0.0 Euro 99.0 96.9 18% -2.1 British pound 17.8 17.7 3% -0.1 Japanese yen 9.2 10.2 2% 1.0 Other currencies 99.6 96.9 18%
Slide 57: Employees as of June 30, 2026
Employees as of June 30, 2026 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q2 2026 Q1 2026 Change Production 287 1,070 140 1,497 1,513 -1 % R&D 158 730 51 939 956 -2 % Sales 549 811 694 2,054 2,060 0% Marketing 77 167 65 309 320 -3 % Administration 72 437 156 665 677
Slide 58: Your contacts
Your contacts Daniel Wendorff Vice President Calendar E-mail: Head of Investor Relations ir@qiagen.com Q3 2026 results November 2026 Phone: +49 2103 29 11322 Internet: E-mail: daniel.wendorff@qiagen.com corporate.QIAGEN.com Q4 2026 results February 2027 Dr. Domenica Martorana Associate Director Shar
Qiagen — Morgan Stanley Healthcare Conference (September 2026) on 6ix